title: Effects of chlormadinone acetate, acetazolamide and oxygen on awake and asleep gas exchange in patients with chronic obstructive pulmonary disease (COPD).
abstract: The purpose of this study was to assess the short-term effects of chlormadinone acetate (CMA), a synthetic progestogen, acetazolamide (ACET) and oxygen on awake and asleep blood gas values. The study was conducted according to a randomized, double-blind and placebo-controlled design in 53 hypoxaemic patients with chronic obstructive pulmonary disease. On the first two consecutive nights, all patients received either room air or oxygen, via a nasal cannula, in random order. They then received either CMA (25 mg), ACET (250 mg) or placebo twice a day, all in identical capsules. On the third study night, after one week of drug treatment, the patients were tested breathing room air. CMA and ACET therapy decreased mean daytime arterial carbon dioxide tension (PaCO2) by 0.7 and 0.5 kPa, respectively, and night-time end-tidal carbon dioxide tension (PETCO2) by 0.5 and 0.3 kPa, respectively. Supplemental oxygen caused increased CO2 retention during the day and night (0.6 and 0.3 kPa, respectively. Daytime arterial oxygen tension (PaO2) increased to the same extent during ACET (1.9 kPa) and oxygen (2.5 kPa). Asleep oxygen saturation improved most with oxygen supplementation (7%), although ACET also caused significant improvement (4%). CMA administration had virtually no effect on mean awake and asleep hypoxaemia. ACET therapy significantly improved subjective sleep quality. On CMA, minute ventilation increased in association with an augmentation of the hypercapnic ventilatory response. ACET treatment increased both hypercapnic and hypoxic ventilatory responses. We conclude from the group of patients with COPD studied, that the short-term effects of ACET treatment on gas exchange compare favourably with those of CMA. Oxygen therapy improves oxygenation slightly more than ACET, but aggravates CO2 retention.
authors.affiliation: Dept of Pulmonary Disease, University of Nijmegen, Dekkerswald, Groesbeek, The Netherlands.
authors.forename: P J
authors.initials: PJ
authors.lastname: Vos
authors.forename: H T
authors.initials: HT
authors.lastname: Folgering
authors.forename: T M
authors.initials: TM
authors.lastname: de Boo
authors.forename: W J
authors.initials: WJ
authors.lastname: Lemmens
authors.forename: C L
authors.initials: CL
authors.lastname: van Herwaarden
mesh_terms: D000086:Acetazolamide / Q000494:pharmacology* / Q000627:therapeutic use; D000368:Aged; D002245:Carbon Dioxide / Q000097:blood*; D002715:Chlormadinone Acetate / Q000494:pharmacology* / Q000627:therapeutic use; D004311:Double-Blind Method; D005260:Female; D006801:Humans; D008173:Lung Diseases, Obstructive / Q000097:blood* / Q000188:drug therapy / Q000503:physiopathology; D008297:Male; D008875:Middle Aged; D010100:Oxygen / Q000097:blood* / Q000494:pharmacology*; D012890:Sleep; D014851:Wakefulness
chemical_list: D002715:Chlormadinone Acetate; D002245:Carbon Dioxide; D000086:Acetazolamide; D010100:Oxygen